论文部分内容阅读
目的观察贝那普利对临床急性脑梗死(ACI)病人血清抵抗素水平的影响及意义。方法选取临床ACI病人62例,随机分为常规治疗组(32例)和贝那普利治疗组(30例),并以25例非脑血管病患者作为对照组。两组ACI病人均给予常规药物治疗2周;治疗组在常规治疗的基础上加用贝那普利10mg,每日1次口服,治疗2周。所有研究对象均测定治疗前后的血压、高敏C-反应蛋白(hs-CRP)和抵抗素,并评定神经功能缺损程度(NDS)评分。结果1)、两组ACI患者血清hs-CRP和抵抗素水平均较对照组显著升高(P<0.01),血清抵抗素水平与NDS呈正相关(r=0.38,P<0.01)。2)、ACI常规治疗组和贝那普利治疗组病人治疗后的hs-CRP和抵抗素水平均明显降低(P<0.05);贝那普利治疗组NDS的下降最为明显(P<0.05)。结论贝那普利能降低ACI病人的抵抗素水平,减少病人的炎症反应,并有助于促进病人神经功能恢复。
Objective To observe the effect and significance of benazepril on serum resistin in patients with acute cerebral infarction (ACI). Methods Sixty-two patients with clinical ACI were randomly divided into routine treatment group (n = 32) and benazepril treatment group (n = 30), and 25 non-cerebrovascular patients as control group. Two groups of ACI patients were given conventional drug treatment for 2 weeks; the treatment group on the basis of conventional treatment plus benazepril 10mg, 1 day orally for 2 weeks. All subjects were measured before and after treatment of blood pressure, high-sensitivity C-reactive protein (hs-CRP) and resistin, and assess the degree of neurological deficit (NDS) score. Results 1) Serum levels of hs-CRP and resistin were significantly increased in both ACI patients (P <0.01) and serum resistin levels were positively correlated with NDS (r = 0.38, P <0.01). 2). The levels of hs-CRP and resistin in ACI conventional treatment group and benazepril treatment group were significantly decreased (P <0.05), and the decline of NDS in benazepril treatment group was the most significant (P <0.05) . Conclusion benazepril can reduce the level of resistin in patients with ACI, reduce the patient’s inflammatory response, and help to promote the recovery of neurological function.